Mesothelioma in South Carolina

South Carolina Mesothelioma Fact Sheet

While mmesothelioma is a problem in all states, the specific incident rate for South Carolina is 0.8 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in SC, recent SC mesothelioma-related court cases, mesothelioma specialists in SC and potential asbestos hotspots in South Carolina.

South Carolina Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of South Carolina

South Carolina Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

South Carolina Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

South Carolina Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

Research

Abstract:DESCRIPTION (provided by applicant): The occupational cancer malignant mesothelioma is newly diagnosed in up to 3,000 persons per year in the US and most of these patients will die within 12 months of diagnosis regardless of treatment. Millions remain at risk in the US and the number at risk is expected to climb in developing nations where asbestos continues to be used, often without protection. In order to significantly impact this disease more needs to be known about the molecular mechanisms required for the initiation and maintenance of the malignant state in the mesothelial cell. Although a number of investigators have described increases in expression of some genes in mesothelioma cells, no oncogenes have been shown to have functional importance. Studies preliminary to this work show that a unique oncogene named CaSm, which is likely to transform cells through its role in RNA message destabilization, has high levels of expression of message and protein in virtually all mesothelioma cell lines and the majority of mesothelioma tumors examined. Further preliminary studies show that antisense CaSm inhibits growth of mesothelioma cells in vitro and in vivo. Antisense CaSm inhibition of growth is associated with cell-specific cell cycle alterations and increased expression of specific cell cycle-associated proteins. From this work we formed the hypothesis that: elevated CaSm expression plays a critical role in the development and maintenance of the malignant phenotype in asbestos-induced malignant mesothelioma To establish the role of CaSm expression in the malignant phenotype of mesothelioma cells, a series of loss of function and gain of function experiments will be performed using sense and antisense strategies, as well as small inhibitory RNAs. Important gain of function experiments will also be performed in vivo through the development of a transgenic mouse which will conditionally express CaSm in a tissue-specific manner. Focus will be placed upon the role of CaSm in regulation of expression of cell cycle proteins. Actinomycin chase and mutation analysis experiments will then be performed to determine if CaSm exerts its effect on cell cycle by destabilizing messages for these proteins. Finally experiments will determine whether asbestos specifically induces the expression of CaSm, and if it does so via reactive oxygen species or via other known mechanisms such as integrin adhesion. We believe these studies will provide exciting information and important insight into this cancer.

Tags: Asbestos, Chemical Related Neoplasm /cancer, Functional /structural Genomics, Gene Expression, Mesothelioma, Neoplasm /cancer Genetics, Oncogene Actinomycin, Cell Cycle Protein, Cell Proliferation, Free Radical Oxygen, Gene Induction /repression, Phenotype 3t3 Cell, Rnase Protection Assay, Scid Mouse, Clinical Research, Human Subject, Transfection /expression Vector, Transgenic Animal

Abstract:

  • Followup Grant: 5R01ES011323-03
  • Followup Grant: 5R01ES011323-04
  • Followup Grant: 5R01ES011323-05

Clinical Trials

Condition: Malignant Mesothelioma

Intervention: Drug: erlotinib hydrochloride

More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: capecitabine
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride; Drug: gemcitabine hydrochloride
More Information

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: gefitinib
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information

Hospitals and Cancer Centers

We do not have any doctors or cancer centers for this state at the moment.

Henderson v. Allied Signal, Inc.
Opinion No. 26322, SUPREME COURT OF SOUTH CAROLINA, March 6, 2007, Heard, April 30, 2007, Filed

Murphy v. Owens-Corning Fiberglas Corp.
[NO NUMBER IN ORIGINAL], SUPREME COURT OF SOUTH CAROLINA, December 8, 2003, Decided

Murphy v. Owens-Corning Fiberglas Corp.
Opinion No. 25740 , SUPREME COURT OF SOUTH CAROLINA, February 6, 2003, Heard February 6, 2003 , October 27, 2003, Filed

Murphy v. Owens-Corning Fiberglas Corp.
Opinion No. 3354, COURT OF APPEALS OF SOUTH CAROLINA, November 7, 2000, Heard , June 11, 2001, Filed

Murphy v. Owens-Corning Fiberglas Corp.
Opinion No. 3203, COURT OF APPEALS OF SOUTH CAROLINA, November 4, 1999, Heard , June 26, 2000, Filed

Rogers v. Kunja Knitting Mills,U.S.A.
Opinion No. 3029, COURT OF APPEALS OF SOUTH CAROLINA, April 15, 1999, Heard , July 26, 1999, Filed

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

  • This field is for validation purposes and should be left unchanged.

Get your free copy of
“Surviving Mesothelioma” Today!